CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alere Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alere Inc.
51 Sawyer Road
Suite 200
Phone: 781-647-3900p:781-647-3900 Waltham, MA  02453-3448  United States
This company was Merged or Acquired on 10/3/2017.
On April 12, 2017 the Audit Committee of the Board of Directors of Alere Inc., after considering the recommendations of management, concluded that the Company’s financial statement as of Sept. 30th, 2016 should not be relied upon. Based on its review to date of certain aspects of revenue recognition at its South Korean and Japanese locations, the Company preliminarily anticipates that the restatement will relate primarily to certain aspects of revenue recognition at the Company’s South Korean location.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Alere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201712/31/2016YesYesYes-Yes

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8099 Health and allied services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Gregg J.Powers 54 5/1/2014 8/19/2013
President, Chief Executive Officer, Director NamalNawana 46 10/25/2014 12/30/2012
Chief Financial Officer, Executive Vice President James F.Hinrichs 49 4/6/2015 4/6/2015
12 additional Officers and Directors records available in full report.

Business Names
Business Name
ABON Biopharm (Hangzhou) Co., Ltd.
Alere (Shanghai) Diagnostics Co., Ltd.
Alere (Shanghai) Medical Sales Co., Ltd.
128 additional Business Names available in full report.

General Information
Outstanding Shares: 87,577,345 (As of 8/1/2017)
Shareholders: 886
Stock Exchange: NYSE
Federal Tax Id: 043565120


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 29, 2023